{
    "clinical_study": {
        "@rank": "6542", 
        "arm_group": {
            "arm_group_label": "Treatment (gemtuzumab ozogamicin)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive gemtuzumab ozogamicin IV over 2 hours on days 1 and 15."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies gemtuzumab ozogamicin in treating patients with relapsed or\n      refractory acute myeloid leukemia or acute promyelocytic leukemia. Monoclonal antibodies,\n      such as gemtuzumab ozogamicin, can block cancer growth in different ways. Some block the\n      ability of cancer to grow and spread. Others find cancer cells and help kill them or carry\n      cancer-killing substances to them."
        }, 
        "brief_title": "Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia", 
        "condition": [
            "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", 
            "Adult Acute Myeloid Leukemia With Del(5q)", 
            "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", 
            "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", 
            "Adult Acute Promyelocytic Leukemia (M3)", 
            "Childhood Acute Promyelocytic Leukemia (M3)", 
            "Recurrent Adult Acute Myeloid Leukemia", 
            "Recurrent Childhood Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Promyelocytic, Acute"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To provide patients with acute myeloid leukemia (AML) or acute promyelocytic leukemia\n      (APL), who have relapsed or who are refractory to standard treatments, with access to\n      gemtuzumab ozogamicin (Mylotarg) when no other comparable or satisfactory alternative\n      therapy is available.\n\n      II. To carefully monitor safety and to report safety information from patients receiving\n      Mylotarg in this setting.\n\n      OUTLINE:\n\n      Patients receive gemtuzumab ozogamicin intravenously (IV) over 2 hours on days 1 and 15.\n\n      After completion of study treatment, patients are followed up every month for 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of relapsed or refractory AML and not candidate for standard consolidation\n             treatment after daunorubicin and cytosine arabinoside OR diagnosis of APL relapsed\n             after tretinoin (ATRA) and arsenic trioxide therapy or APL with persisting or rising\n             blasts, and no other comparable or satisfactory alternative therapy available\n             (including patients not eligible for, or who have access to, investigational\n             therapies via a clinical trial)\n\n          -  Patients must have an initial diagnosis of AML, biphenotypic acute leukemia, or APL\n\n          -  Patients must have cluster of differentiation (CD)33 positivity of > 30%\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 3 / Karnofsky > 60%\n\n          -  Total bilirubin within normal institutional limits\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             =< 2 x institutional upper limit of normal\n\n          -  It is deemed ethical to provide an experimental drug (e.g., Mylotarg) that is\n             associated with hepatotoxicity (veno-occlusive disease [VOD]) and myelosuppression\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control; abstinence) prior to receiving Mylotarg\n             and for the duration of treatment; should a woman become pregnant or suspect she is\n             pregnant while receiving treatment with Mylotarg, she should inform her treating\n             physician immediately\n\n          -  Ability to understand and the willingness to sign a written Institutional Review\n             Board (IRB)-approved informed consent document\n\n        Exclusion Criteria:\n\n          -  Patients may not currently be receiving any other investigational agents for leukemia\n\n          -  Patients with known untreated hepatitis C\n\n          -  Uncontrolled intercurrent illness including, but not limited to active liver disease,\n             or psychiatric illness/social situations that would limit compliance with study\n             requirements\n\n          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if\n             the mother is treated with Mylotarg\n\n          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral\n             therapy are ineligible; appropriate studies will be undertaken in patients receiving\n             combination antiretroviral therapy when indicated\n\n          -  Patients with a known hypersensitivity to gemtuzumab ozogamicin or its parts:\n             recombinant humanized anti-CD33 monoclonal (hP67.6) antibody, calicheamicin\n             derivatives or other ingredients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "3 Months"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01869803", 
            "org_study_id": "CCCWFU# 99213", 
            "secondary_id": [
                "NCI-2013-00965", 
                "P30CA012197"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (gemtuzumab ozogamicin)", 
                "description": "Given IV", 
                "intervention_name": "gemtuzumab ozogamicin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody", 
                    "CDP-771", 
                    "CMA-676", 
                    "Mylotarg"
                ]
            }, 
            {
                "arm_group_label": "Treatment (gemtuzumab ozogamicin)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies, Monoclonal", 
                "Gemtuzumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 15, 2013", 
        "location": {
            "contact": {
                "email": "lrellis@wakehealth.edu", 
                "last_name": "Leslie R. Ellis", 
                "phone": "336-713-5847"
            }, 
            "facility": {
                "address": {
                    "city": "Winston-Salem", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27157"
                }, 
                "name": "Comprehensive Cancer Center of Wake Forest University"
            }, 
            "investigator": {
                "last_name": "Leslie R. Ellis", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Compassionate Use of Gemtuzumab Ozogamicin (Mylotarg) for Treatment of Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL)", 
        "overall_official": {
            "affiliation": "Comprehensive Cancer Center of Wake Forest University", 
            "last_name": "Leslie Ellis", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Access to gemtuzumab ozogamicin", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "measure": "Incidence of adverse events as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01869803"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Comprehensive Cancer Center of Wake Forest University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Comprehensive Cancer Center of Wake Forest University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}